Objective The use of molecular markers can identify a subgroup of tumors with distinct recurrence patterns. The present study aimed to characterize the immunohistochemical expression of vimentin (VIM), of E-cadherin (CDH1), and of cytokeratin 5 (CK5) in patients with invasive ductal carcinomas (IDCs). Methods We have constructed a tissue microarray (TMA) from 87 patients with IDC of the breast. Immunohistochemistry (IHC) was performed to study the expression of estrogen and progesterone receptors (ER and PgR), human epidermal growth factor receptor 2 (HER2), VIM, CDH1, CK5, and Ki67. The tumors were classified as luminal A and B (n ¼ 39), HER2 enriched (n ¼ 25), and triple-negative (TNBC) (n ¼ 23), based on the IHC expression. Conclusion Our findings suggest that the expression of VIM and CDH1 can identify a subset of IDCs of the breast with a mesenchymal phenotype associated with poor prognosis, high-grade lesion, and high mitotic index.
Introduction
Based on its genomic profile, breast cancer can be classified in six subtypes (luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, basal-like, claudin-low, and normal-like). 1, 2 This classification stratifies patients with adverse prognostic characteristics, and the basal-like and claudin-low subtypes confer the shortest overall survival.
3-6
Immunohistochemical phenotyping based on estrogen and progesterone receptors (ER and PgR), HER2, and Ki67 expression has been proposed as an alternative to classify breast cancer into different subtypes. According to this immunophenotyping approach, breast cancer can be divided into luminal A (HR þ , HER2-, low Ki67 index), luminal B (HRþ with HER2þ or HER2-plus high Ki67 index), HER2-enriched (HR-, HER2 þ ) and triple negative (TNBC) (HR-and HER2-).
7-10
Triple negative tumors tend to have a worse prognosis than luminal A, luminal B, and HER2-enriched tumors, and no specific targeted TNBC therapy has been developed yet.
11-14
Although TNBC has been characterized as a pathological entity, there is significant biological heterogeneity within these tumors. 13, 15 The basal-like phenotype is reported as the main TNBC subtype. 8, 16, 17 However, all the other molecular subtypes can occur. 16, 17 The use of immunohistochemistry (IHC) to identify different subgroups of TNBC tumors has been proposed. Cytokeratin 5 (CK5) and epidermal growth factor receptor (EGFR) expressions have been reported as markers of basal-like carcinomas. 7, 8, 14, 15, 18 In fact, CK5 expression has been reported to be the most accurate basal-like marker.
7,19-22
Breast cancers that have arisen from basal cells are supposed to have a mesenchymal phenotype. 17, 23, 24 The claudin-low group lacks cell-cell junction proteins, and has features resembling the epithelial-mesenchymal transition (EMT) activation. 2, 13, 17, 25 Additionally, some studies have suggested that there is a subgroup with a quintuple-negative profile (HR-, HER2-, CK5-, and EGFR-) that exhibits a worse prognosis when compared with CK5þ or EGFRþ TNBC. 18, 26 Thus, the use of EMT markers can identify an undifferentiated subgroup with a possibly highly aggressive clinical behavior.
4,17,27
Most investigated and reported EMT markers include the Ecadherin (CDH1), a cell surface protein responsible for the adhesion of epithelial cells. Downregulation in CDH1 is highly associated with EMT, and partial or total loss of CDH1 expression is associated with more aggressive behavior and poor prognosis. 
Methods Sample Selection
We have selected all patients (n ¼ 175) with IDC of the breast subjected to surgery at Hospital 
Tissue Microarray
Core biopsies (diameter ¼ 1mm) were punched from 2 representative areas of each tumor of each of the 87 donor paraffin blocks and arrayed into a new recipient paraffin block using a manual tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA). Three 1 μm-thick sections were cut from a tissue microarray (TMA) paraffin block using a paraffin tape-transfer system (Instrumedics Inc., Saint Louis, MO, USA). The slides were dipped in paraffin to prevent oxidation. One section was stained with hematoxylin and eosin (H&E) to confirm the presence of the tumor by light microscopy.
Immunohistochemistry
The immunohistochemical staining was performed using the Novolink Max Polymer Detection System (Leica Biosystems, Wetzlar, Germany). The sections were deparaffinized in xylene and rehydrated through a series of graded alcohols. The endogenous peroxidase activity was blocked for 30 minutes in a solution containing 0.3% of hydrogen peroxide to block non-specific immunoassaying. The sections were then placed in a 10 mM citrate buffer and submitted to heat retrieval using a vapor lock for 40 minutes. After the antigen retrieval, the specimens were allowed to cool for 30 minutes, and then incubated at 4°C overnight with a primary antibody. The dilution and source of the primary antibodies used in the present study were: anti-human ER (1:100, clone 6F11) (Leica Biosystems, Wetzlar, Germany), anti-human PgR (1:100, clone 1A6) (Leica Biosystems, Wetzlar, Germany), anti-human-Ki67 (1:200) (Leica Biosystems, Wetzlar, Germany), anti-human CK5 (HPA024467, 1:100) (Sigma-Aldrich, St. Louis, MO, USA), anti-human vimentin (1:100, clone V9) (Biocare Medical, Pacheco, CA, US), and anti-human CDH1 (1:50, clone HECD-1) (Biocare Medical, Pacheco, CA, USA). After overnight incubation with the primary antibody, the slides were incubated with a postprimary solution for 30 minutes and then incubated with the polymer for another 30 minutes (both provided by the Novolink Max Polymer Detection System). The reaction was developed with diaminobenzidine (DAB), followed by hematoxylin counterstaining. The slides were then dehydrated in an ethanol series and mounted with Permount (Fischer, Fair Lawn, NJ, USA). The DAKO Herceptest (Agilent Technologies, Santa Clara, CA, USA) was used for HER2 protein staining following the protocol of the manufacturer. Digital analysis: In brief, the Ki67 TMA slide was scanned at 20 Â magnification on an Aperio Scanscope CS (Aperio Technologies Inc., Vista, CA, USA). The Aperio Scanscope CS is a whole-slide imaging system that scans entire tissue sections and registers the image stripes into one file. The image was uploaded onto an Aperio Spectrum Plus server, and then we used the TMA Laboratory module to break the image into its logical components of sectors, rows, columns, and cores. The Nuclear V9.1 (Aperio Technologies, Vista, CA) image analysis algorithms were used for the quantification of the Ki67 staining. In general, this algorithm begins by splitting the color data in the image into a maximum of 3-color channels. In this case, we separated the channels into a blue hematoxylin channel and a brown DAB channel. The 
Statistical Analysis
The expression of VIM and CDH1proteins and other categorical variables were compared using the standard X 2 test or the Fisher exact test. The difference in the Ki67 staining index was evaluated using the median test, while the difference in age between groups was assessed using the t-test. The disease-free and overall survival interval was calculated from the date of diagnosis, and the survival curves were derived from Kaplan-Meier estimates and compared by logrank tests. The JMP version 10 software (SAS, Cary, NC, USA) Rev Bras Ginecol Obstet was used for the statistical analyses. The significance was established as p < 0.05 (two-sided). We have analyzed the disease-free and overall survival according to tumor subtypes, CK5 expression, and VIM þ / CDH1 -/low phenotype. We did not find a significant difference in disease-free and overall survival between luminal A, luminal B, HER2-enriched, and TNBC tumors, and there was no association between CK5 expression and survival (data not shown). In patients with VIM þ /CDH1 -/low phenotype and non-VIM þ /CDH1 -/low phenotype tumors, the 5-year disease-free survival rates were of 61.5% and 83.7%, and the 5-year overall survival rates were 51.2% and 83.5%, respectively. ►Fig. 2 shows the Kaplan-Meier curves for disease-free and overall survival according to the VIM þ / CDH1 -/low phenotype, which were statically significant (p ¼ 0.02 and p ¼ 0.03 [log-rank test], respectively).
Results

Expression of CK5, VIM and CDH1 in IDCs
Discussion
Breast cancer is a biologically and clinically heterogeneous disease. [1] [2] [3] 5, [7] [8] [9] [10] [15] [16] [17] This complexity is a key factor for treatment failure. 1, [10] [11] [12] 35, 36 Immunohistochemistry has been used to analyze the expression of specific proteins in cancer cells to identify subsets of tumors with specific characteristics, enabling a personalized treatment.
7-10,18,26
We have demonstrated that there is a subset of invasive breast carcinomas with characteristics of a mesenchymal VIM þ /CDH1 -/low phenotype, suggesting that the use of However, this is a retrospective and single institution study including a relatively small number of samples. A large prospective study is necessary to confirm our findings.
Conclusion
In conclusion, the IHC identification of a subset of IDC with mesenchymal phenotype suggests the selection of an aggressive IDC subtype and should prompt further investigation on this field.
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